

Auryxia® (ferric citrate) – First-time authorized generic alternative

- On March 20, 2025, Mylan/Viatris launched an authorized generic alternative of Keryx Biopharmaceuticals/Akebia Therapeutics' Auryxia (ferric citrate) tablets.
- Auryxia is approved for the following indications:
 - For the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis
 - For the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.